Extended indication Extension of indication to include treatment of narcolepsy with or without cataplexy in adolescents and children from the age of 6 years.
Therapeutic value Possible added value
Registration phase Registration application pending

Product

Active substance Pitolisant
Domain Neurological disorders
Reason of inclusion Indication extension IND
Main indication Sleep disorders
Extended indication Extension of indication to include treatment of narcolepsy with or without cataplexy in adolescents and children from the age of 6 years.
Proprietary name Wakix
Manufacturer Bioprojet1
Mechanism of action Other
Route of administration Oral
Therapeutical formulation Tablet
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Unknown
Particularity Unknown
ATMP No
Submission date June 2022
Expected Registration May 2023
Orphan drug No
Registration phase Registration application pending

Therapeutic value

Therapeutic value Possible added value

This assessment does not indicate any potential inclusion in the package.

Dosage per administration nog niet bekend

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Additional remarks Nog niet bekend

Expected cost per patient per year

References medicijnkosten.nl
Additional remarks De huidige behandeling kost < 4500 euro per jaar gezien het een behandeling van < 12 euro betreft voor 18 mg tabletten 1 maal per dag. Het is nog onduidelijk of ook hier een dosering van 18 mg per dag zal komen te gelden, indien dat het geval is zullen de kosten ook maximaal 4500 euro per patient per jaar kosten.

Potential total cost per year

Additional remarks Nog niet bekend

Off label use

Off label use Unknown
Additional remarks Nog niet bekend

Indication extension

Indication extensions Yes
Additional remarks Betreft uitbreiding naar kinderen vanaf 6 jaar,

Other information